Drug major Cipla Ltd on Saturday (January 20) said it has rescheduled its Board of Directors meeting originally slated for Thursday, January 25, 2024, to Monday, January 22, 2024.
The meeting is set to address and approve the unaudited standalone and consolidated financial results for the quarter and nine months ending on December 31, 2023.
This comes after
Cipla encountered a situation where parts of its potential standalone financial results for the nine months ending December 31, 2023, were found circulating on social media.
The company promptly issued a cautionary statement, clarifying that these results are yet to undergo the necessary review, finalization, and approval processes.
Investors have been strongly advised against relying on any such information, emphasizing the importance of awaiting the official, verified financial disclosures.
The company highlighted that making investment decisions based on unverified information poses a risk, and individuals should exercise caution in this regard.
In light of the rescheduled meeting, Cipla has also declared the closure of its "Trading Window" for dealing in the company's securities.
Shares of
Cipla Ltd ended at ₹1,312.60, down by ₹10.70, or 0.81% on the BSE.
